ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Drug Manufacturers - Specialty & Generic

Healthcare
$71.47 -1.76%

-$1.42 today

Market cap
$1.62B
Beta
0.44
P/E (TTM)
18.5
EPS (TTM)
$4.29
52W Low $62.61High $99.50

Volume 0.29M

Average 0.35M

ANIP Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

ANI Pharmaceuticals, Inc.NASDAQ: ANIP

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin widens to 12.4%

Net margin was 12.4% in Q1 FY2026, up 4.5 pp from a year earlier. On a trailing-twelve-month basis it was 9.7%, up 12.8 pp year over year. Over 3 fiscal years it widened by 24.0 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 6 analysts of 18.3% for the fiscal year ending Dec 2026, up from 8.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
12.4%+1.3 pp QoQ
Last fiscal yearDec 2025
8.9%+11.9 pp YoY
LTMMar 2026
9.7%+12.8 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+4.5 pp+13.0 pp+8.5 pp
1 year+11.9 pp+9.5 pp-2.4 pp
3 years+24.0 pp+9.7 pp-14.3 pp
5 years+9.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
8.9%
Year-over-year change
+11.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How ANIP compares with its peers on the latest reported figures

  • ANIP's LTM Mar 2026 net margin of 9.7% is the 2nd highest of the 11 companies compared; the peer median is 0.6%.
  • Its year-over-year change of +12.8 pp is the 2nd highest of 10, against a peer median of +4.6 pp.
  • Over three fiscal years its change of +24.0 pp compares with a peer median of +10.9 pp.
ANIP Competitors Peer median
Net Margin for ANIP and competitors
Company Period LTM level YoY 3-year change
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202611.0% -8.5 pp-4.7 pp
ANIPANI Pharmaceuticals, Inc.LTM Mar 20269.7% +12.8 pp+24.0 pp
COLLCollegium Pharmaceutical, Inc.LTM Mar 20269.4% +2.8 pp+13.4 pp
RDYDr. Reddy's Laboratories LimitedLTM Sep 20268.5% -8.7 pp-5.6 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 20265.0% +4.9 pp+8.3 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 20264.1% +5.0 pp+24.6 pp
VTRSViatris Inc.LTM Jun 2026-2.8% +21.8 pp-37.4 pp
HROWHarrow Health, Inc.LTM Mar 2026-5.6% +4.6 pp+14.0 pp
BHCBausch Health Companies Inc.LTM Jun 2026-10.1% -11.1 pp+4.3 pp
EOLSEvolus, Inc.LTM Mar 2026-14.4% +6.0 pp+32.7 pp
LFCRLifecore Biomedical, Inc.LTM Mar 2026-25.2% —+74.8 pp
Peer median (excluding ANIP) 0.6%+4.6 pp+10.9 pp

Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue216.14M316.39M486.82M614.38M883.37M
Cost of Revenue100.61M138.79M181.51M250.21M432.73M
Gross Profit115.53M177.6M305.3M364.17M450.64M
Gross Margin53.5%56.1%62.7%59.3%51.0%
Research & Development11.37M22.32M34.29M44.58M51.66M
Selling, General & Admin84.29M124.04M161.7M249.64M317.75M
Operating Expenses155.32M212.88M258.33M363.58M369.41M
Depreciation & Amortization47.25M59.65M59.79M67.73M91.42M
EBITDA3.12M25.04M106.6M63.12M207.27M
EBITDA Margin1.4%7.9%21.9%10.3%23.5%
Operating Income(39.79M)(35.28M)46.97M584K81.23M
Operating Margin-18.4%-11.2%9.6%0.1%9.2%
Interest Income00000
Interest Expense11.92M28.05M26.94M17.6M20.06M
Other Income / Expenses(16.27M)(27.38M)(27.1M)(22.8M)14.56M
Income Before Tax(56.06M)(62.67M)19.87M(22.21M)95.79M
Pre-Tax Margin-25.9%-19.8%4.1%-3.6%10.8%
Income Tax Expense(13.46M)(14.77M)1.09M(3.69M)17.45M
Net Income(42.6M)(47.9M)18.78M(18.52M)78.34M
Net Margin-19.7%-15.1%3.9%-3.0%8.9%
EPS (Basic)(3.40)(3.05)0.95(1.04)3.50
EPS (Diluted)(3.40)(3.05)0.94(1.04)3.32
Weighted Avg Shares12.6M16.26M18M19.32M20.05M
Weighted Avg Shares (Diluted)12.6M16.26M18.19M19.32M21.23M

ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Intrinsic Alpha fair value

Locked

Current Price

$71.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.